American Journal of Cardiology
Volume 103, Issue 6 , Pages 785-790, 15 March 2009

Left Ventricular Function After ST-Elevation Myocardial Infarction in Patients Treated With Primary Percutaneous Coronary Intervention and Abciximab or Tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial)

  • Nevio Taglieri, MD

      Affiliations

    • Istituto di Cardiologia, Università di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
    • Corresponding Author InformationCorresponding author: Tel: 39-051-636-4475; fax: 39-051-636-4477
  • ,
  • Francesco Saia, MD, PhD

      Affiliations

    • Istituto di Cardiologia, Università di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
  • ,
  • Vincenzo Guiducci, MD

      Affiliations

    • Unità Operativa di Cardiologia Interventistica, Ospedale S. Maria Nuova, Reggio Emilia, Italy
  • ,
  • Stefano Tondi, MD

      Affiliations

    • Unità Operativa di Cardiologia, Ospedale di Baggiovara, Modena, Italy
  • ,
  • Federico Conrotto, MD

      Affiliations

    • Unità Operativa di Cardiologia, Ospedale Molinette, Torino, Italy
  • ,
  • Cinzia Marrozzini, MD

      Affiliations

    • Istituto di Cardiologia, Università di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
  • ,
  • Guido Rocchi, MD

      Affiliations

    • Istituto di Cardiologia, Università di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
  • ,
  • Elena Biagini, MD, PhD

      Affiliations

    • Istituto di Cardiologia, Università di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
  • ,
  • Maria Letizia Bacchi Reggiani, MSc

      Affiliations

    • Istituto di Cardiologia, Università di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
  • ,
  • Paola Giacometti, MD

      Affiliations

    • Unità Operativa di Cardiologia Interventistica, Ospedale S. Maria Nuova, Reggio Emilia, Italy
  • ,
  • Giancarlo Piovaccari, MD

      Affiliations

    • Unità Operativa di Cardiologia, Ospedale degli Infermi, Rimini, Italy
  • ,
  • Antonio Manari, MD

      Affiliations

    • Unità Operativa di Cardiologia Interventistica, Ospedale S. Maria Nuova, Reggio Emilia, Italy
  • ,
  • Antonio Marzocchi, MD

      Affiliations

    • Istituto di Cardiologia, Università di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
  • ,
  • FATA Investigators

Received 29 August 2008; received in revised form 13 November 2008; accepted 13 November 2008. published online 22 January 2009.

Abciximab therapy during primary percutaneous coronary intervention (PCI) has shown to ameliorate left ventricular (LV) function recovery in patients with ST elevated myocardial infarction. High-dose bolus tirofiban has similar effect on platelet inhibition. Whether this is associated with comparable efficacy on LV function recovery remains unclear. We sought to evaluate the impact on LV function of high-dose bolus tirofiban or abciximab in patients undergoing primary PCI with the predictors of favorable (≥50%) LV ejection fraction (EF) and LV function recovery at 30 days. We studied 314 patients (abciximab n = 154; tirofiban n = 160) undergoing primary PCI in the randomized Facilitated Angioplasty with Tirofiban or Abciximab (FATA) trial. LVEF was assessed within 48 hours and at 30 days after primary PCI. In patients with systolic dysfunction at baseline, LV function recovery was defined by either increase of LVEF ≥10% compared with baseline or LVEF ≥50%. Similar LVEF was observed in the 2 groups postprocedure (abciximab 49.7 ± 10.1% vs tirofiban 49.3 ± 10.1%, p = 0.9) and at 30 days (abciximab 53.1 ± 9.8% vs tirofiban 52.5 ± 10.2%, p = 0.6). Independent predictors of 30-day LVEF ≥50% were preprocedure Thrombolysis In Myocardial Infarction flow class >0 (odds ratio = 2.4, 95% confidence interval 1.32 to 4.34), anterior location (odds ratio = 0.25, 95% confidence interval 0.15 to 0.42), and age (odds ratio = 0.97, 95% confidence interval 0.95 to 0.99). Preprocedure Thrombolysis In Myocardial Infarction flow grade >0 was the only predictor of LV function recovery (odds ratio = 6.73, 95% confidence interval 2.69 to 16.88). In conclusion, this study showed no difference in LV function recovery in patients undergoing primary PCI treated either with abciximab or high-dose bolus tirofiban. Preprocedure Thrombolysis In Myocardial Infarction flow grade >0 seems to be the most important predictor of favorable LVEF and LV function recovery at 30 days.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The FATA trial was a spontaneous, noncompany promoted study almost entirely funded by each participating center and from the Fondazione Fanti-Melloni, a charitable institution linked to the University of Bologna. The study was partially supported with a research grant by Merck & Co., Inc. The company had no role in the study design, the analysis and interpretation of the data, or the drafting or revision of the final manuscript.

PII: S0002-9149(08)02084-5

doi:10.1016/j.amjcard.2008.11.029

American Journal of Cardiology
Volume 103, Issue 6 , Pages 785-790, 15 March 2009